ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0672

Pharmacokinetics (PK), Effectiveness and Safety of Open-label (OL) Tofacitinib for the Treatment of Moderate to Severe Skin Involvement in Young Adults with SLE
Abstract Number: 1085

Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment
Abstract Number: 0384

Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study
Abstract Number: 1005

Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib
Abstract Number: 0303

Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Abstract Number: 0108

Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)
Abstract Number: 0014

Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease
Abstract Number: 2054

Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients
Abstract Number: 2545

Phosphodiesterase 1B Contributes to Neuropsychiatric Manifestations in Lupus-Prone Mice Through Microglial Activation
Abstract Number: 1175

Physical Activity and Symmetry Following Total Knee Arthroplasty:Results of an Exploratory Trial
Abstract Number: 1302

Physician Knowledge, Attitudes and Perceived Barriers to Recommending the Recombinant Varicella Zoster Vaccine
Abstract Number: 1053

Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases
Abstract Number: 1413

Pilot Trial of Ustekinumab for Primary Sjogren’s Syndrome
Abstract Number: 0182

Pilot Volunteer Lupus Navigator Program – Leveraging Community Health Workers to Address Social Determinants of Health in SLE
Abstract Number: 0350

Piloting an Adaptation of the Making It Work Program for Systemic Sclerosis: Promising Effects on Job Related Self-efficacy and Risk of Work Disability

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].